Cash Flow from Financial Activities: The net amount of cash transactions used in funding activities.
NewAmsterdam Pharma Company N.V. (NAMS) had Cash Flow from Financial Activities of $22.11M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$3.70M |
|
$-64.14M |
|
-- |
|
$3.70M |
|
$68.56M |
|
$-64.86M |
|
$0.73M |
|
$-64.14M |
|
$-64.14M |
|
$-64.14M |
|
$-64.14M |
|
$-64.14M |
|
$-64.14M |
|
$-64.86M |
|
$-64.81M |
|
123.37M |
|
123.37M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$659.21M |
|
$0.41M |
|
$45.24M |
|
$704.45M |
|
$72.97M |
|
-- |
|
$0.06M |
|
$73.03M |
|
$631.42M |
|
$631.08M |
|
$631.42M |
|
117.65M |
|
| Cash Flow Statement Financials | |
$-69.82M |
|
$-16.27M |
|
|
Cash Flow from Financial Activities |
$22.11M |
$491.32M |
|
$425.51M |
|
$-65.81M |
|
$36.38M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1752.61% |
|
-1752.61% |
|
-- |
|
-1732.91% |
|
-1732.91% |
|
$-69.94M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-10.16% |
|
-10.16% |
|
-9.10% |
|
-10.16% |
|
$5.37 |
|
$-0.57 |
|
$-0.57 |
|